Wright Medical Enters Injectable BVF Market, Joining J&J/DePuy, Synthes
This article was originally published in The Gray Sheet
Executive Summary
Wright Medical Group will market its MIIG 115 minimally invasive injectable Osteoset bone graft substitute system primarily to trauma surgeons supported by a sales force of 220 commissioned reps in the U.S
You may also be interested in...
Wright Medical Planning Lineage Ceramic-On-Ceramic Hip Launch In Q4
Wright Medical and Stryker Howmedica Osteonics are both awaiting ceramic material supplier GMP certification prior to final FDA approval for their respective Lineage and Trident ceramic-on-ceramic hip prostheses, expected in late 2002
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.